SCHEMBL5807495

SCHEMBL5807495

Cc1c([C@H](C)C(=O)NCC(=O)O)c2c(F)c(O)ccc2n1C(=O)c1ccc(F)c(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.35
AKR1C2 P52895 4/20 0.35
PTGS2 P35354 3/20 0.33
PTGS1 P23219 1/20 0.33
HIF1A Q16665 1/20 0.32
THRB P10828 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
HPGD P15428 1/20 0.31
CHRNA1 P02708 1/20 0.31
CHRNG P07510 1/20 0.31
CHRNB1 P11230 1/20 0.31
CHRNB2 P17787 1/20 0.31
SLC6A2 P23975 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
SLC6A3 Q01959 1/20 0.31
CHRND Q07001 1/20 0.31
SHMT1 P34896 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5807492 1.00 AKR1C3 (0.35) AKR1C3AKR1C2PTGS2PTGS1HIF1A
SCHEMBL5807488 1.00 AKR1C3 (0.35) AKR1C3AKR1C2PTGS2PTGS1HIF1A
SCHEMBL5555406 0.93 MEN1 (0.32) AKR1C3AKR1C2PTGS2PTGS1MEN1
SCHEMBL5555402 0.93 MEN1 (0.32) AKR1C3AKR1C2PTGS2PTGS1MEN1
SCHEMBL5554076 0.92 AKR1C3 (0.35) AKR1C3AKR1C2PTGS2PTGS1HIF1A
SCHEMBL5811171 0.91 AKR1C3 (0.36) AKR1C3AKR1C2PTGS2PTGS1HPGD
SCHEMBL5811164 0.91 AKR1C3 (0.36) AKR1C3AKR1C2PTGS2PTGS1HPGD
SCHEMBL5558763 0.90 AKR1C3 (0.43) AKR1C3AKR1C2PTGS2PTGS1HIF1A
SCHEMBL5558768 0.90 AKR1C3 (0.43) AKR1C3AKR1C2PTGS2PTGS1HIF1A
SCHEMBL5558758 0.90 AKR1C3 (0.43) AKR1C3AKR1C2PTGS2PTGS1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006050120-A2 SYNTHESIS OF COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2006-05-11 WO disclosed
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed
US-20050032747-A1 COX-2 and FAAH inhibitors POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032747-A1 COX-2 and FAAH inhibitors FAAH2, FAAH, PTGS2 AKR1C3 585/4885AKR1C2 342/4885PTGS2 3/4885
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 AKR1C3 577/4885AKR1C2 563/4885PTGS2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.